Key Takeaways
- BLS puts the median annual wage for medical scientists at $107,520 and biochemists at $109,740, but total compensation at commercial-stage biotechs frequently runs 30 to 50 percent higher once equity and bonus are included
- Personnel costs typically represent 50 to 70 percent of total operating expenses at pre-revenue biotech companies, making talent the single largest budget line from day one
- The U.S. life sciences sector faces a structural talent gap: STEM supply pipelines produce roughly 60 percent of the qualified graduates needed to fill projected openings through 2032
- Contract Research Organizations charge 20 to 40 percent less than fully in-house clinical operations for equivalent trial execution, and offshore biostatistics and regulatory writing teams in India run $15 to $35 per hour versus $80 to $140 per hour for U.S. equivalents
- Biotech turnover runs 15 to 18 percent annually; replacing a senior scientist costs an estimated 100 to 150 percent of their annual salary when recruiting, onboarding, and lost productivity are included
The distance between a biotech seed round and a product launch can stretch eight to fifteen years. Labor accounts for the majority of what gets spent in between. Unlike manufacturing or retail, biotech cannot substitute capital for headcount in early research stages. Scientists, clinical operations people, regulatory affairs managers, and bioinformatics analysts do not have off-the-shelf replacements, and the market for all of them has tightened steadily since 2020.
The data below comes from the Bureau of Labor Statistics, Mercer/Radford life sciences compensation surveys, the Biotechnology Innovation Organization, Deloitte's life sciences outlook, and industry filings. The goal is a working baseline for founders, CFOs, and HR leaders who need real numbers, not estimates built on vibes.
1. Wages by role: 2026 national medians
The BLS Occupational Employment and Wage Statistics program, updated through May 2024 and published in March 2025, is the most reliable public baseline for life sciences compensation. The figures below reflect national medians. Biotech hubs including the Boston/Cambridge corridor, the San Francisco Bay Area, San Diego, and the Research Triangle in North Carolina typically run 15 to 35 percent above these medians, driven by cost-of-living adjustments and local competition for the same pool of candidates.
| Role | Median Annual Wage | BLS SOC Code |
|---|---|---|
| Biochemist / Biophysicist | $109,740 | 19-1021 |
| Medical Scientist (excl. epidemiologist) | $107,520 | 19-1042 |
| Microbiologist | $96,180 | 19-1022 |
| Biomedical Engineer | $99,550 | 17-2031 |
| Statistician (Biostatistics) | $100,910 | 15-2041 |
| Chemical Engineer (Process/Mfg) | $112,100 | 17-2041 |
| Biological Technician | $50,070 | 19-4021 |
| Chemical Technician | $52,940 | 19-4031 |
| Regulatory Affairs Specialist | $92,500 | 13-1041 (est.) |
| Clinical Research Coordinator | $74,260 | 29-9021 |
| Medical and Health Services Manager | $119,840 | 11-9111 |
| Science Research Administrator | $78,340 | 11-9121 |
Sources: BLS OEWS May 2024, released March 2025. Regulatory Affairs Specialist figure is a composite estimate from BLS management analyst data and Radford Global Compensation Database 2025.
Base salary is only part of the picture at commercial-stage companies. Radford's 2025 Global Life Sciences Survey found that annual cash bonuses for research scientists average 12 to 18 percent of base pay, and long-term incentives (stock options or RSUs) add another 20 to 40 percent of base salary in grant value for mid-level and senior roles. Stack on benefits at 25 to 30 percent and the fully loaded cost of a senior scientist at a $115,000 base reaches $175,000 to $195,000 per year.
2. Labor as a percentage of operating budget
In most industries, companies can invest in equipment or software to reduce headcount. In early-stage biotech, that trade-off mostly does not exist. R&D progress depends on the scientists doing the work, and the equipment budget is secondary.
Analysis of 10-K filings from pre-revenue biotech companies consistently shows that personnel costs account for 50 to 70 percent of total operating expenses before a product reaches Phase III trials. For a company burning $40 million per year, that is $20 to $28 million in payroll and benefits, before clinical site costs, manufacturing, or regulatory fees.
At commercial-stage biotechs, the ratio shifts as manufacturing, distribution, and sales force costs grow. Deloitte's 2025 Life Sciences Industry Outlook found that labor costs represent approximately 35 to 45 percent of total operating expenses for companies with at least one marketed product. R&D-only functions at the same companies hold closer to 55 to 65 percent.
Some numbers from SEC filings and industry benchmarks:
- G&A payroll at small and mid-size biotechs typically runs $3 to $8 million annually for core back-office and executive functions (Axios life sciences filing benchmarks, 2025).
- Clinical operations staffing for a single Phase II trial requires 8 to 25 full-time equivalents depending on site count and indication, representing $1.2 to $4.5 million in annual payroll before CRO fees.
- Regulatory and medical affairs teams at companies filing their first NDA or BLA typically employ 6 to 18 people, with total salary budgets ranging from $900,000 to $3.2 million.
3. The talent shortage reshaping biotech hiring
The life sciences labor market does not behave like most white-collar sectors. Biotech competes for the same STEM graduates as pharma, medical device, academic research, and tech companies that have built health and diagnostics businesses. The competition has a supply problem underneath it.
The Biotechnology Innovation Organization's 2025 workforce report found that the U.S. life sciences industry needs to add roughly 85,000 to 100,000 workers per year through 2032 to meet projected demand. STEM pipelines, including undergraduate and graduate programs in biology, chemistry, bioinformatics, and biomedical engineering, currently produce enough qualified graduates to fill roughly 55 to 60 percent of those openings.
The numbers on the gap:
- Average time to fill a senior scientist or principal scientist role runs 90 to 120 days in major biotech hubs, compared to 45 to 60 days for non-technical management roles (Mercer Life Sciences Talent Pulse, 2025).
- CBRE's 2025 Life Sciences Talent and Labor Report identified more than 65,000 active unfilled life sciences positions across the top 10 U.S. biotech clusters at any given time during 2024.
- Large pharmaceutical companies with structured graduate recruitment programs and stronger brand recognition capture a disproportionate share of top-tier Ph.D. graduates. Roughly 43 percent of life sciences Ph.D. graduates entering industry roles in 2024 joined companies with more than 5,000 employees (NIH-funded workforce tracking data, 2025).
- Demand for bioinformatics scientists grew 28 percent between 2021 and 2024, while supply of candidates with both biology and software skills grew by approximately 11 percent over the same period (ISCB workforce survey, 2024).
The shortage is not uniform. Biological technician roles and research associate positions are easier to fill, but they churn faster as candidates use them as stepping stones to graduate programs or higher-paying tech roles.
4. Turnover costs and retention pressure
High turnover is a recurring cost in biotech, not a surprise. The life sciences sector recorded an average voluntary turnover rate of 15 to 18 percent in 2024, according to Mercer and Radford's compensation benchmarks. That figure climbs to 22 to 26 percent at companies that just failed a Phase III trial, when scientists reassess their options quickly.
Replacing a departing scientist is expensive:
- Recruiting fees through a specialized life sciences search firm: typically 20 to 30 percent of first-year salary, or $22,000 to $35,000 on a $115,000 base.
- A new research scientist reaches full productivity in 6 to 12 months at most biotechs. During that ramp, output runs at roughly 50 to 75 percent of a fully ramped employee.
- Knowledge loss is particularly sharp in early-stage programs where two or three scientists hold the primary understanding of a compound's behavior or manufacturing quirks.
All-in, replacing a senior scientist earning $115,000 to $130,000 costs an estimated $115,000 to $195,000, or one to one-and-a-half times annual salary, when recruiting fees, signing bonuses, ramp time, and management overhead are counted. For a 30-person research team running 16 percent annual turnover, that works out to five departures per year and roughly $575,000 to $975,000 in replacement costs.
This is part of why biotech has pushed non-core scientific functions toward CRO or contract arrangements. Keeping a specialist on payroll for work that comes up quarterly carries the full turnover risk. A contract engagement does not.
5. CRO and outsourced research costs
Contract Research Organizations handle a growing share of biotech's clinical and preclinical work. The global CRO market reached approximately $72 billion in 2024 and is projected to grow at 8 to 10 percent annually through 2030, driven by biotech and specialty pharma outsourcing clinical trials, bioanalytical testing, and regulatory writing (Grand View Research, 2025; ICON Plc investor disclosures, 2025).
CRO outsourcing versus in-house clinical operations, by function:
| Function | In-House Annual Cost (FTE + overhead) | CRO / Outsourced Rate | Estimated Savings |
|---|---|---|---|
| Clinical Research Associate (on-site monitoring) | $130,000 - $160,000 | $95 - $130/hr (pass-through) | 15 - 30% |
| Biostatistician | $140,000 - $175,000 | $85 - $120/hr | 10 - 25% |
| Regulatory Writer | $110,000 - $145,000 | $75 - $110/hr | 10 - 20% |
| Data Manager (clinical data management) | $95,000 - $130,000 | $60 - $95/hr | 15 - 25% |
| Pharmacovigilance Specialist | $105,000 - $140,000 | $70 - $100/hr | 15 - 30% |
Note: In-house costs include base salary, benefits (25-30%), and allocated overhead. CRO hourly rates are pass-through billing rates. Savings estimates account for CRO margin but exclude management overhead on the biotech side.
For a Phase II trial with 40 to 80 sites, fully outsourcing clinical operations to a full-service CRO costs 20 to 40 percent less than building an equivalent in-house team, but requires stronger project management on the sponsor side. The Tufts Center for the Study of Drug Development estimated in its 2025 benchmarking report that hybrid outsourcing models (a strategic CRO partner plus a small internal team) achieve roughly 30 percent savings against fully internal operations with lower delivery risk than full outsourcing.
6. Offshore and virtual support costs
Not every biotech function requires U.S.-based talent. Regulatory document formatting, clinical data entry and coding, literature reviews, medical writing support, pharmacovigilance case processing, and administrative support for clinical trial logistics can all be handled remotely at significantly lower cost.
India is the main hub for offshore life sciences support. Major CROs including Syneos Health, ICON, and Parexel run large India-based delivery centers, and a growing number of specialized boutique providers work directly with smaller biotechs.
Approximate offshore rate ranges for common support functions:
- Regulatory document formatting and publishing: $12 - $22/hr (India) vs. $55 - $80/hr (U.S.)
- Biostatistics support and SAS programming: $18 - $35/hr (India) vs. $75 - $120/hr (U.S.)
- Medical writing support: $20 - $40/hr (India, MBBS or M.Pharm background) vs. $80 - $140/hr (U.S.)
- Pharmacovigilance case processing: $14 - $28/hr (India) vs. $50 - $85/hr (U.S.)
- Clinical data entry and coding: $10 - $20/hr (India) vs. $40 - $65/hr (U.S.)
General administrative support is another category that often stays fully in-house when it does not need to. A biotech VP of Clinical Operations managing 12 investigator sites typically spends 8 to 12 hours per week on logistics and correspondence that does not require a scientific background. Delegating those tasks to a trained virtual assistant at $12 to $18 per hour, instead of absorbing the work at a VP's fully loaded rate of $80 to $110 per hour, saves $50,000 to $80,000 per year per executive.
The pattern in pharmaceutical industry staffing costs follows the same offshore adoption curve: functions that can be standardized and documented move offshore; those that require deep institutional knowledge or face-to-face investigator contact stay onshore.
7. How biotech staffing costs compare to adjacent industries
Biotech pays more than most of healthcare industry staffing for equivalent educational credentials, but competes directly with technology industry staffing costs for bioinformatics and data engineering talent. The comparison table below shows where biotech sits relative to peers.
| Industry | Avg. Annual Labor Cost per FTE (all roles) | Turnover Rate | Avg. Time to Fill (senior roles) |
|---|---|---|---|
| Biotech / Life Sciences | $118,000 - $145,000 | 15 - 18% | 90 - 120 days |
| Technology (software) | $138,000 - $172,000 | 13 - 21% | 60 - 90 days |
| Healthcare (clinical) | $82,000 - $105,000 | 16 - 22% | 45 - 75 days |
| Pharmaceutical (large) | $122,000 - $155,000 | 10 - 14% | 75 - 100 days |
Sources: BLS OEWS May 2024; Mercer 2025 Life Sciences Compensation Survey; Radford Global Compensation Database 2025; NSI Nursing Solutions 2025 Report.
Large pharmaceutical companies have lower turnover than biotech because they offer more structured career paths, larger total compensation packages, and lower single-program risk. Smaller biotechs compete on equity upside and mission and absorb higher attrition as a consequence.
Key takeaways
-
Personnel expenses account for 50 to 70 percent of total operating budgets at pre-revenue biotechs. Every hire is a major financial commitment and every departure costs one to one-and-a-half times annual salary to unwind.
-
BLS data shows core biotech roles with medians between $96,000 and $112,000. In major hubs like Boston and the Bay Area, total compensation for the same roles reaches $150,000 to $200,000 when equity is included.
-
STEM graduate supply fills roughly 55 to 60 percent of projected annual demand through 2032. Companies waiting for the talent market to loosen are likely to wait a long time.
-
CRO outsourcing cuts clinical costs 20 to 40 percent for functions that do not require continuous scientific judgment. Hybrid models (strategic CRO partner plus a small internal team) tend to perform better than either extreme.
-
Regulatory publishing, data entry, pharmacovigilance processing, medical writing support, and executive administration are all functions where offshore and virtual support generates real savings without touching the science.
-
At 15 to 18 percent turnover and $115,000 to $195,000 per replacement, a 30-person team is spending $345,000 to nearly $1 million per year just cycling through departures. Retention improvements translate directly into runway.